

Predicting Alzheimer's disease development: A comparison of cognitive criteria and associated neuroimaging biomarkers

Brandy L Callahan^{a,b}, Joel Ramirez^b, Courtney Berezuk^b, Simon Duchesne^{a,c}, Sandra E Black^b

^a Centre de recherche de l'Institut universitaire en santé mentale de Québec, Québec (QC) ^b Sunnybrook Research Institute, University of Toronto, Toronto (ON)

^c Département de radiologie, Faculté de médecine, Université Laval, Québec (QC)

BACKGROUND. Currently, there exist multiple criteria for diagnosing mild cognitive impairment (MCI).^{1,2,3} All require the presence of "objective impairment" in one or more cognitive domains, typically including memory. Four critical issues need clarification regarding the operationalization of "objective cognitive impairment":

- 1 **What cut-off?** -1, -1.5 or -2 SD?
- 2 **How many tests?** Is one sufficient?
- 3 **Test other domains?** Language, executive functions?
- 4 **Consider biomarkers?** Genetic? Imaging?

PARTICIPANTS

- 494 non-demented seniors with 24-month follow-up from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

COGNITIVE MEASURES

- Mini-Mental State Exam (MMSE)
- Logical Memory Story A – Delay (LM-II)
- Auditory Verbal Learning Test – Delay (AVLT)
- Category Fluency (animals)
- Boston Naming Test (BNT)
- Trails A & B (B/A ratio was used)

BIOMARKERS

- APOE ϵ_4 status
- Hippocampal (HP) & whole brain volume (BPF)
- White-matter hyperintensity (WMH) volume
- Ventricular cerebrospinal fluid (vCSF)

Main predictors. Six binary variables were created:

- Score < -1 SD \times 1 memory test
 - Score < -1.5 SD \times 1 memory test
 - Score < -2 SD \times 1 memory test
 - Score < -1 SD \times 2 memory tests
 - Score < -1.5 SD \times 2 memory tests
 - Score < -2 SD \times 2 memory tests
- LM-II *or* AVLT
LM-II *and* AVLT

RESULTS




Figure 1. Areas under the curve (AUC) for six cut-offs.

Figure 2. Sensitivity, specificity and accuracy of different cut-off scores in 494 non-demented participants at baseline.



Table 1. Variables predicting Alzheimer's disease at 24 months in addition to selected cut-off scores.

Predictor	<-1 SD on two tests	<-1.5 SD on one test	<-2 SD on one test
Block 1: Main predictors			
Age	$p = .146$	$p = .997$	$p = .403$
Education	$p = .780$	$p = .870$	$p = .668$
Sex	$p = .662$	$p = .917$	$p = .528$
MMSE	$p < .001$	$p < .001$	$p < .001$
Selected cut-off	$p < .001$	$p < .001$	$p < .001$
Block 2: Non-memory tests			
Category Fluency	$p = .227$	$p = .163$	$p = .211$
BNT	$p = .167$	$p = .109$	$p = .052$
Trails B/A ratio	$p = .130$	$p = .033$	$p = .017$
Block 3: Biomarkers			
APOE ϵ_4 (1 allele)	$p = .055$	$p = .055$	$p = .060$
APOE ϵ_4 (2 alleles)	$p = .016$	$p = .021$	$p = .019$
Total HP volume	$p = .326$	$p = .081$	$p = .115$
BPF	$p = .123$	$p = .030$	$p = .078$
WMH	$p = .121$	$p = .654$	$p = .609$
vCSF	$p = .240$	$p = .687$	$p = .382$

CONCLUSION. Episodic memory impairment in MCI should be defined as scores <-1 SD on at least two measures. If one test is used, a more stringent cut-off should be applied and executive functioning abilities or whole-brain volume should be considered. When possible, APOE ϵ_4 status should be ascertained to optimize prediction of conversion to dementia.

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: **The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.** *Alzheimer's Dement* 2011, 7:270-279.
2. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*. 5th edition. Arlington, VA: American Psychiatric Publishing; 2013.
3. Petersen RC: **Mild cognitive impairment as a diagnostic entity.** *J Intern Med* 2004, 256:183-194.

